aduhelm
Washington (AFP) - The US drug regulator on Thursday said only people with mild dementia should receive the first new Alzheimer's medicine in decades, after facing intense backlash from many in the medical community over its authorization. Biogen's Aduhelm received an "accelerated approval" by the Food and Drug Administration in June, despite the fact that an independent expert panel advising the agency found insufficient evidence of its benefit. "Since the agency approved Aduhelm, prescribers and other stakeholders have expressed confusion regarding the intended population for treatment," FDA...
AFP
When the FDA announced on Monday that it had approved a new Alzheimer’s drug from Biogen, a biotech company based in Massachusetts, economic analysts were not enthusiastic. Though the new drug, Aduhelm, presents some hope to patients and families because it has the potential to slow early-on cognitive decline, there is not yet enough evidence to prove its actual effectiveness, at least not enough to validate its $56,000 annual cost. While its momentum comes from the fact that it is the first drug of its kind for Alzheimer’s in the past two decades, the proposed price is higher than some analys...
uPolitics.com
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら